The lipid and non-lipid effects of statins
- 6 June 2003
- journal article
- review article
- Published by Elsevier BV in Pharmacology & Therapeutics
- Vol. 99 (1), 95-112
- https://doi.org/10.1016/s0163-7258(03)00055-x
Abstract
No abstract availableKeywords
This publication has 149 references indexed in Scilit:
- Coronary Heart Disease in Patients With Low LDL-CholesterolCirculation, 2002
- Modulation of COX-2 Expression by Statins in Human Aortic Smooth Muscle CellsPublished by Elsevier BV ,2001
- New Evidence for Beneficial Effects of Statins Unrelated to Lipid LoweringArteriosclerosis, Thrombosis, and Vascular Biology, 2001
- Atorvastatin Upregulates Type III Nitric Oxide Synthase in Thrombocytes, Decreases Platelet Activation, and Protects From Cerebral Ischemia in Normocholesterolemic MiceStroke, 2000
- Lipophilic HMG-CoA reductase inhibitor has an anti-inflammatory effect: Reduction of MRNA levels for interleukin-1β, interleukin-6, cyclooxygenase-2, and p22phox by regulation of peroxisome proliferator-activated receptor α (PPARα) in primary endothelial cellsLife Sciences, 2000
- Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril)The American Journal of Cardiology, 1999
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell lineInternational Journal of Immunopharmacology, 1996
- Clinical Pharmacokinetics of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase InhibitorsClinical Pharmacokinetics, 1996
- Diurnal variation of HMG-CoA reductase activity in rat liver peroxisomesBiochemical and Biophysical Research Communications, 1987